U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H16N4O7S
Molecular Weight 384.364
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ANA-975

SMILES

CC(=O)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]1OC(C)=O)N2C(=O)SC3=C2N=C(N)N=C3

InChI

InChIKey=ZWELIJXAKMASLK-UGKPPGOTSA-N
InChI=1S/C14H16N4O7S/c1-5(20)23-9-7(4-19)25-12(10(9)24-6(2)21)18-11-8(26-14(18)22)3-16-13(15)17-11/h3,7,9-10,12,19H,4H2,1-2H3,(H2,15,16,17)/t7-,9-,10-,12-/m1/s1

HIDE SMILES / InChI

Molecular Formula C14H16N4O7S
Molecular Weight 384.364
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

ISATORIBINE, a guanosine analog, is an immunopotentiating agent. It is a selective agonist of toll‐like receptor 7, a pattern-recognition receptor that activates the innate immune response.

Approval Year

PubMed

PubMed

TitleDatePubMed
Masked oral prodrugs of toll-like receptor 7 agonists: a new approach for the treatment of infectious disease.
2006-08
Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection.
2005-09
Broad-spectrum activity of 8-chloro-7-deazaguanosine against RNA virus infections in mice and rats.
1995-03
Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections.
1994-10
Alkylpurines as immunopotentiating agents. Synthesis and antiviral activity of certain alkylguanines.
1993-10-29
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
1991-10
Guanosine analogues. Synthesis of nucleosides of certain 3-substituted 6-aminopyrazolo[3,4-d]pyrimidin-4(5H)-ones as potential immunotherapeutic agents.
1990-08
Antiviral activity of the novel immune modulator 7-thia-8-oxoguanosine.
1990-02
Roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semliki Forest virus infections in mice.
1990-02
Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents.
1990-01
Broad-spectrum in vivo antiviral activity of 7-thia-8-oxoguanosine, a novel immunopotentiating agent.
1989-09
Patents

Patents

Substance Class Chemical
Created
by admin
on Tue Apr 01 16:29:57 GMT 2025
Edited
by admin
on Tue Apr 01 16:29:57 GMT 2025
Record UNII
5UN5EF99CE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ANA-975
Code English
AN 975
Preferred Name English
((2R,3R,4R,5R)-4-ACETOXY-5-(5-AMINO-2-OXO-THIAZOLO(4,5-D)PYRIMIDIN-3-YL)-2-(HYDROXYMETHYL)TETRAHYDROFURAN-3-YL) ACETATE
Systematic Name English
ISOTORABINE
Common Name English
THIAZOLO(4,5-D)PYRIMIDIN-2(3H)-ONE, 5-AMINO-3-(2,3-DI-O-ACETYL-.BETA.-D-RIBOFURANOSYL)-
Systematic Name English
Code System Code Type Description
PUBCHEM
11234476
Created by admin on Tue Apr 01 16:29:57 GMT 2025 , Edited by admin on Tue Apr 01 16:29:57 GMT 2025
PRIMARY
CAS
847453-47-8
Created by admin on Tue Apr 01 16:29:57 GMT 2025 , Edited by admin on Tue Apr 01 16:29:57 GMT 2025
PRIMARY
FDA UNII
5UN5EF99CE
Created by admin on Tue Apr 01 16:29:57 GMT 2025 , Edited by admin on Tue Apr 01 16:29:57 GMT 2025
PRIMARY
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Class: Antiviral, Nucleoside; Mechanism of Action: Interferon alpha stimulant, Natural killer cell stimulant, Toll-like receptor 7 agonist; Highest Development Phases: Discontinued for Hepatitis B, Hepatitis C; Most Recent Events: 26 Jul 2007 Discontinued - Phase-I for Hepatitis C treatment in Europe (PO), 26 Jul 2007 Discontinued - Phase-I for Hepatitis C treatment in United Kingdom (PO), 26 Jul 2007 Discontinued - Preclinical for Hepatitis C treatment in USA (PO)
Related Record Type Details
ACTIVE MOIETY